SynthesisAdvances in rheumatology (London, England)2026
Incidence and determinants of anxiety and depression in childhood-onset systemic lupus erythematosus: a systematic review and meta-analysis of proportion.
Synthesis in Advances in rheumatology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood-onset systemic lupus erythematosus (cSLE) is a rare and severe autoimmune disorder with impactful physical and psychological impacts. While depression and anxiety are well-recognized in adult SLE, their incidence and determinants in cSLE remain less clear.
methodsWe performed a systematic review and meta-analysis following PRISMA guidelines. We searched five databases from inception to January 2025. Our inclusion criteria were studies of pediatric patients (≤18 years) meeting 1997 ACR, and 2021 SLICC diagnostic criteria for SLE and reporting anxiety or depression rates. Data of the demographics, disease characteristics, and medications were extracted, and meta-regression explored potential determinants.
results36 studies fulfilled inclusion criteria. Pooled analyses revealed a 14% prevalence of anxiety and 19% prevalence of depression. Exploratory meta-regression indicated that immunosuppressive therapies were associated with modest but statistically significant reductions in both depression and anxiety. By contrast, hematologic complications showed a positive association with risk of mood disorders. Oral steroids showed inconsistent relationships with psychological outcomes.
conclusionsAnxiety and depression are common in cSLE, we need to integrate screening for them in rheumatologic and mental health care. Close monitoring, early screening, and targeted interventions can help detect the psychological burden and potentially improve adherence to therapy and long-term outcomes. TRIAL REGISTRATION NUMBER: Not applicable.
Indexed as
Identifiers
41645357What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.